PROTAC BRD9 Degrader-7

PROTAC BRD9 Degrader-7

• UNSPSC Description: PROTAC BRD9 Degrader-7 is an orally active and selective degrader of BRD9 with a DC50 of 1.02 nM. PROTAC BRD9 Degrader-7 has superior oral activity with a Cmax of 3436.95 ng/mL[1].
• Target Antigen: PROTACs
• Type: Reference compound
• Related Pathways: PROTAC
• Applications: Cancer-programmed cell death
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/protac-brd9-degrader-7.html
• Purity: 99.29
• Solubility: DMSO : 70 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: O=C(N(C)C=C1C2=CC(OC)=C(CN3CCN(C4=CC=C5C(C(N(C6C(NC(CC6)=O)=O)C5=O)=O)=C4)CC3)C(OC)=C2)C7=C1C=CC=C7
• Molecular Weight: 649.69
• References & Citations: [1]Jingyu Zhang, et al. Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia, European Journal of Medicinal Chemistry, Volume 262, 2023, 115872.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported